Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Nature

Volumn 467, Issue 7315, 2010, Pages 596-599

  Bollag, Gideon ^a   Hirth, Peter ^a   Tsai, James ^a   Zhang, Jiazhong ^a   Ibrahim, Prabha N ^a   Cho, Hanna ^a   Spevak, Wayne ^a   Zhang, Chao ^a   Zhang, Ying ^a   Habets, Gaston ^a   Burton, Elizabeth A ^a   Wong, Bernice ^a   Tsang, Garson ^a   West, Brian L ^a   Powell, Ben ^a   Shellooe, Rafe ^a   Marimuthu, Adhirai ^a   Nguyen, Hoa ^a   Zhang, Kam Y J ^a   Artis, Dean R ^a   Schlessinger, Joseph ^b   Su, Fei ^c   Higgins, Brian ^c   Iyer, Raman ^c   Dandrea, Kurt ^d   Koehler, Astrid ^c   Stumm, Michael ^c   Lin, Paul S ^a   Lee, Richard J ^c   Grippo, Joseph ^c   Puzanov, Igor ^e   Kim, Kevin B ^f   Ribas, Antoni ^g   McArthur, Grant A ^h   Sosman, Jeffrey A ^e   Chapman, Paul B ⁱ   Flaherty, Keith T ^d,j   Xu, Xiaowei ^d   Nathanson, Katherine L ^d   Nolop, Keith ^a   more..

^a PLEXXIKON INC   (United States)

^b YALE UNIVERSITY   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PLX 4032; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; MUTANT PROTEIN; SULFONAMIDE; VEMURAFENIB;

CANCER; CYTOLOGY; DOSE-RESPONSE RELATIONSHIP; ENZYME ACTIVITY; EXPERIMENTAL STUDY; INHIBITION; INHIBITOR; MUTATION; REGRESSION ANALYSIS; RNA; TOXICOLOGY; TUMOR;

ARTICLE; BRAF GENE; CANCER GROWTH; CANCER PATIENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HUMAN TISSUE; MELANOMA; METASTASIS; ONCOGENE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR XENOGRAFT; ALLELE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOG; DRUG EFFECTS; DRUG SCREENING; ENZYME SPECIFICITY; ENZYMOLOGY; GENETICS; MACACA FASCICULARIS; METABOLISM; MUTATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; RAT; SIGNAL TRANSDUCTION;

ALLELES; ANIMALS; DOGS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INDOLES; MACACA FASCICULARIS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION; NEOPLASM METASTASIS; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS B-RAF; RATS; SUBSTRATE SPECIFICITY; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956513286     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature09454     Document Type: Article

References (28)

1. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
2. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
3. Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
4. Yang, H. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518-5527 (2010).
5. Flaherty, K. et al. Inhibition ofmutated, activated BRAF inmetastaticmelanoma. N. Engl. J. Med. 363, 809-819 (2010).
6. Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041-3046 (2008).
7. Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
8. Koch, W.H.Technology platforms for pharmacogenomic diagnostic assays.Nature Rev. Drug Discov. 3, 749-761 (2004).
9. Rubinstein, J. C. et al. Incidence of the V600Kmutationamongmelanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J. Transl. Med. 8, 67 (2010).
10. Esteve-Puig, R., Canals, F., Colome, N., Merlino, G. and Recio, J. A. Uncoupling of the LKB1-AMPKa energy sensorpathway by growthfactors and oncogenicBRAFV600E. PLoS ONE 4, e4771 (2009).
11. Zheng, B. et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell 33, 237-247 (2009).
12. Søndergaard, J. N. et al. Differential sensitivity ofmelanoma cell lines with BRAFV600E mutation to the specific B-Raf inhibitor PLX4032. J. Transl. Med. 8, 39 (2010).
13. Arnault, J. P. et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J. Clin. Oncol. 27, e59-e61 (2009).
14. Dubauskas, Z. et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associatedwithsorafenib. Clin.Genitourin.Cancer 7,20-23 (2009).
15. Kong, H. H. et al. Keratoacanthomas associated with sorafenib therapy. J.Am. Acad. Dermatol. 56, 171-172 (2007).
16. Schwartz, G. K. et al. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. J. Clin. Oncol. 27, 3513 (suppl.), (2009).
17. Kefford, R. et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J. Clin. Oncol. 28, 8503 (suppl.), (2010).
18. Heidorn, S. J. et al. Kinase-deadBRAF andoncogenicRAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
19. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. and Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
20. Courtois-Cox, S. et al. A negative feedback signaling network underlies oncogeneinduced senescence. Cancer Cell 10, 459-472 (2006).
21. Dougherty, M. K. et al. Regulation of Raf-1 by direct feedbackphosphorylation.Mol. Cell 17, 215-224 (2005).
22. Hall-Jackson, C. A. et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6, 559-568 (1999).
23. Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F. and Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542-545 (2009).
24. Pratilas, C. A. et al. V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl Acad. Sci. USA 106, 4519-4524 (2009).
25. Kolch, W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nature Rev. Mol. Cell Biol. 6, 827-837 (2005).
26. Pollock, P. M. et al. High frequency of BRAF mutations in nevi. Nature Genet. 33, 19-20 (2003).
27. Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724 (2005).
28. Korn, E. L. et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 26, 527-534 (2008).